Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment

Bispecific T‐cell Engagers (BiTE®) antibody constructs enable a polyclonal T‐cell response to cell‐surface tumor‐associated antigens, bypassing the narrow specificities of T‐cell receptors and the need for antigen presentation through the major histocompatibility complex pathways. Blinatumomab, a CD...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuraszeck, T, Kasichayanula, S, Benjamin, JE
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
State of the Art
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763312/
https://www.ncbi.nlm.nih.gov/pubmed/28182247
http://dx.doi.org/10.1002/cpt.651
_version_ 1783291859801473024
author Yuraszeck, T
Kasichayanula, S
Benjamin, JE
author_facet Yuraszeck, T
Kasichayanula, S
Benjamin, JE
author_sort Yuraszeck, T
collection PubMed
description Bispecific T‐cell Engagers (BiTE®) antibody constructs enable a polyclonal T‐cell response to cell‐surface tumor‐associated antigens, bypassing the narrow specificities of T‐cell receptors and the need for antigen presentation through the major histocompatibility complex pathways. Blinatumomab, a CD19xCD3 BiTE® antibody construct, received accelerated approval for the treatment of relapsed/refractory Philadelphia chromosome negative acute lymphoblastic leukemia. Herein we review the pharmacology, safety, and efficacy observed in studies of blinatumomab and other BiTE® antibody constructs. Quantitative systems pharmacology is envisioned as a means to optimize dosing decisions for trials in which BiTE® antibody constructs are administered as monotherapy or in combination with other immunotherapies.
format Online
Article
Text
id pubmed-5763312
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-57633122018-01-17 Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment Yuraszeck, T Kasichayanula, S Benjamin, JE Clin Pharmacol Ther State of the Art Bispecific T‐cell Engagers (BiTE®) antibody constructs enable a polyclonal T‐cell response to cell‐surface tumor‐associated antigens, bypassing the narrow specificities of T‐cell receptors and the need for antigen presentation through the major histocompatibility complex pathways. Blinatumomab, a CD19xCD3 BiTE® antibody construct, received accelerated approval for the treatment of relapsed/refractory Philadelphia chromosome negative acute lymphoblastic leukemia. Herein we review the pharmacology, safety, and efficacy observed in studies of blinatumomab and other BiTE® antibody constructs. Quantitative systems pharmacology is envisioned as a means to optimize dosing decisions for trials in which BiTE® antibody constructs are administered as monotherapy or in combination with other immunotherapies. John Wiley and Sons Inc. 2017-04-18 2017-05 /pmc/articles/PMC5763312/ /pubmed/28182247 http://dx.doi.org/10.1002/cpt.651 Text en © 2017 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle State of the Art
Yuraszeck, T
Kasichayanula, S
Benjamin, JE
Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment
title Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment
title_full Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment
title_fullStr Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment
title_full_unstemmed Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment
title_short Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment
title_sort translation and clinical development of bispecific t‐cell engaging antibodies for cancer treatment
topic State of the Art
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763312/
https://www.ncbi.nlm.nih.gov/pubmed/28182247
http://dx.doi.org/10.1002/cpt.651
work_keys_str_mv AT yuraszeckt translationandclinicaldevelopmentofbispecifictcellengagingantibodiesforcancertreatment
AT kasichayanulas translationandclinicaldevelopmentofbispecifictcellengagingantibodiesforcancertreatment
AT benjaminje translationandclinicaldevelopmentofbispecifictcellengagingantibodiesforcancertreatment

Ejemplares similares